Supriya Lifescience shares jumped over 16% after the company posted a strong Q4FY26 performance, with PAT rising 47% YoY and revenue surging 50%. Robust demand across therapeutic segments, improved capacity utilisation, and traction in regulated markets supported growth. The stock remains in an uptrend despite overbought technical indicators.
Market Samachar is a news aggregator. This article was originally published by Stocks-Markets-Economic Times. Tap the button above to read the full story on their site.